BA
The Boeing Company
BA's fundamentals are strong: its operating margin went from −10% to 10% and revenue grew 18%. Its PE isn't a useful guide right now because of how its recent earnings were reported.
DCM
Universal Safety Products, Inc.
There isn't enough reported data to score DCM yet.
BA Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Healthy | |
| Stable | |
| Under pressure |
BA's profitability is currently healthy, and its revenue and cash flow are stable, but its balance sheet is under pressure.
DCM Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Weak |
DCM's revenue, profitability, cash flow and balance sheet are all currently weak.
BA PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 18x | $172 | — |
| Cheap | 51x | $496 | +189% |
| Fair | 82x | $790 | +360% |
| Expensive | 91x | $876 | +411% |
Historical ranges are pointers, not guarantees.
BA's PE is 18x, but its earnings don't support one, so it isn't a reliable read right now.
DCM PE Valuation
DCM has no meaningful PE right now: it lost money over the past year.
BA Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Returning to profit | |
| Growth | |
| Improving | |
| Limited | |
| Low |
Analysts expect BA to return to profit, with revenue growing. However, they disagree widely on these estimates.
DCM Forward outlook
There aren't enough analyst estimates for DCM to show an outlook.
BA Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $9.66 | +$23.38 |
| Q2 2026 | $2.78 | +$19.33 |
| Q1 2026 | $2.53 | +$20.49 |
| Q4 2025 | $2.48 | +$20.84 |
| Q3 2025 | -$13.72 | -$0.83 |
| Q2 2025 | -$16.55 | -$10.93 |
| Q1 2025 | -$17.96 | -$14.42 |
| Q4 2024 | -$18.36 | -$14.69 |
BA has the edge over DCM on earnings quality, reporting a profit while its opponent remains loss making.
DCM Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$2.05 | -272% |
| Q1 2026 | -$1.04 | -573% |
| Q4 2025 | -$0.08 | +$0.46 |
| Q3 2025 | $0.51 | +$0.61 |
| Q2 2025 | $1.19 | +$1.62 |
| Q1 2025 | $0.22 | +$0.39 |
| Q4 2024 | -$0.54 | -460% |
| Q3 2024 | -$0.10 | -138% |
DCM has swung to a loss: it lost $2.05 per share over the past year, after a profit the year before.
BA Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.2B | +3.9% |
| Q2 2026 | $24.6B | +8% |
| Q1 2026 | $22.2B | +14% |
| Q4 2025 | $23.9B | +57% |
| Q3 2025 | $23.3B | +30% |
| Q2 2025 | $22.7B | +35% |
| Q1 2025 | $19.5B | +18% |
| Q4 2024 | $15.2B | -31% |
BA has the edge over DCM on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 1.5% | +22 points |
| Q2 2026 | 0.6% | +1.4 points |
| Q1 2026 | 2% | -0.3 points |
| Q4 2025 | 37% | +61 points |
| Q3 2025 | -21% | +12 points |
| Q2 2025 | -0.8% | +5.7 points |
| Q1 2025 | 2.4% | +2.9 points |
| Q4 2024 | -25% | -26 points |
BA has the edge over DCM on profitability, with a higher operating margin.
DCM Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $109.6K | -97% |
| Q1 2026 | $240.4K | -96% |
| Q4 2025 | $22.5K | -100% |
| Q3 2025 | $760K | -89% |
| Q2 2025 | $3.8M | -17% |
| Q1 2025 | $6.2M | +29% |
| Q4 2024 | $5.5M | +19% |
| Q3 2024 | $7.2M | +94% |
DCM's revenue has slid since its 2024 peak: $109,559 last quarter, down 97% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | -673% | -659 points |
| Q1 2026 | -419% | -435 points |
| Q4 2025 | -9700% | -9685 points |
| Q3 2025 | -122% | -132 points |
| Q2 2025 | -14% | -5.3 points |
| Q1 2025 | 16% | +25 points |
| Q4 2024 | -16% | -18 points |
| Q3 2024 | 9.4% | +14 points |
DCM's operating margin was −673% last quarter, down 659 points from the same quarter a year ago, near the bottom of its range since 2019.
BA Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $464M | +95% |
| Q2 2026 | $631M | +$831M |
| Q1 2026 | -$1.5B | +$836M |
| Q4 2025 | $375M | +$4.5B |
| Q3 2025 | $238M | +$2.2B |
| Q2 2025 | -$200M | +$4.1B |
| Q1 2025 | -$2.3B | +$1.6B |
| Q4 2024 | -$4.1B | -239% |
BA has the edge over DCM on cash generation, producing positive trailing cash flow while its opponent burns cash.
DCM Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | -$733.2K | -127% |
| Q1 2026 | -$811.4K | -$499.8K |
| Q4 2025 | -$2.6M | -202% |
| Q3 2025 | $1.2M | +$3.3M |
| Q2 2025 | $2.8M | +$4M |
| Q1 2025 | -$311.6K | -182% |
| Q4 2024 | $2.5M | +$3M |
| Q3 2024 | -$2.1M | -541% |
DCM's free cash flow was −$3M over the past year, against $3M the year before.
BA Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.3% | +2.1M shares |
| 1 year | +4.3% | +32.8M shares |
| 3 years | +31% | +186M shares |
| 5 years | +35% | +204M shares |
| Available history | +40% | +227M shares |
BA has the edge over DCM on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2019 | — |
DCM Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +27% | +624K shares |
| 1 year | +27% | +624K shares |
| 3 years | +27% | +624K shares |
| 5 years | +27% | +624K shares |
| Available history | +27% | +624K shares |
DCM has 3M diluted shares, up 27% from a year ago.
BA Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 3.0x | Elevated |
| Q2 2026 | 5.7x | High |
| Q1 2026 | 6.0x | High |
| Q4 2025 | 6.9x | High |
| Q2 2024 | 361.8x | High |
| Q1 2024 | 36.1x | High |
| Q4 2023 | 36.4x | High |
| Q3 2023 | 96.1x | High |
BA's net debt is about 3.0 years of its operating earnings (EBITDA), down from more than 20 years a year ago.
DCM Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2025 | 4.3x | High |
| Q4 2023 | 4.3x | High |
| Q3 2023 | 1.9x | Healthy |
| Q2 2023 | 2.0x | Healthy |
| Q1 2023 | 1.3x | Healthy |
| Q4 2022 | -0.2x | Net Cash |
| Q3 2022 | -0.5x | Net Cash |
| Q2 2022 | -26.9x | Net Cash |
DCM's net debt is about 4.3 years of its operating earnings (EBITDA), up from 1.3 years a year ago.
BA Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 31.1 | Neutral |
| Stochastic | 9.6 | Oversold |
BA's weekly RSI is 31 (neutral) and its Stochastic is 10 (oversold).
DCM Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 37.5 | Neutral |
| Stochastic | 5.7 | Oversold |
DCM's weekly RSI is 37 (neutral) and its Stochastic is 6 (oversold).
BA PE vs Industrials Sector
| Metric | BA | Sector median | Relative |
|---|---|---|---|
| PE | 18x | 24x | 26% below |
| PE % | 0 | 58 | 58 pts below |
BA is trading at 18x earnings, a 26% discount to the Industrials sector's median of 24x, though its earnings don't support one.
DCM PE vs Industrials Sector
| Metric | DCM | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 24x | — |
DCM has no meaningful PE right now: it lost money over the past year.
BA Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $184.6 | 7.1% below |
| 20 week MA | $203.8 | 16% below |
| 50 week MA | $215.5 | 20% below |
| 100 week MA | $205.9 | 17% below |
| 200 week MA | $200.6 | 14% below |
BA is in a downtrend: it's below all five of its weekly moving averages, and 14% below its 200-week average.
DCM Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.16 | 27% below |
| 20 week MA | $4.32 | 30% below |
| 50 week MA | $5.02 | 40% below |
| 100 week MA | $4.10 | 26% below |
| 200 week MA | $3.05 | 0.7% below |
DCM is in a downtrend: it's below all five of its weekly moving averages, and 0.7% below its 200-week average.
BA Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $330.1 | $217.2 | -34% |
| 2021 | $217.2 | $204.2 | -6% |
| 2022 | $204.2 | $189.1 | -7.4% |
| 2023 | $189.1 | $260.7 | +38% |
| 2024 | $260.7 | $180.7 | -31% |
| 2025 | $180.7 | $216.4 | +20% |
| 2026 YTD | $216.4 | $171.6 | -21% |
BA has the edge over DCM on returns for 2026, with the stronger performance.
DCM Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $0.61 | $2.91 | +377% |
| 2021 | $2.91 | $3.64 | +25% |
| 2022 | $3.64 | $2.10 | -42% |
| 2023 | $2.10 | $1.66 | -21% |
| 2024 | $1.66 | $2.31 | +39% |
| 2025 | $2.31 | $5.00 | +116% |
| 2026 YTD | $5.00 | $3.03 | -39% |
DCM's yearly returns have swung widely, from +377% in 2020 to −42% in 2022. It's down 39% so far in 2026.